AU2018207946B2 - Probiotic compositions and uses thereof - Google Patents

Probiotic compositions and uses thereof Download PDF

Info

Publication number
AU2018207946B2
AU2018207946B2 AU2018207946A AU2018207946A AU2018207946B2 AU 2018207946 B2 AU2018207946 B2 AU 2018207946B2 AU 2018207946 A AU2018207946 A AU 2018207946A AU 2018207946 A AU2018207946 A AU 2018207946A AU 2018207946 B2 AU2018207946 B2 AU 2018207946B2
Authority
AU
Australia
Prior art keywords
cells
mean
placebo
treatment
probiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018207946A
Other languages
English (en)
Other versions
AU2018207946A1 (en
Inventor
Daniel AGARDH
Lars Niklas Larsson
Irini LAZOU AHRÉN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Probi AB
Original Assignee
Probi AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1700542.2A external-priority patent/GB201700542D0/en
Priority claimed from GBGB1709731.2A external-priority patent/GB201709731D0/en
Application filed by Probi AB filed Critical Probi AB
Publication of AU2018207946A1 publication Critical patent/AU2018207946A1/en
Application granted granted Critical
Publication of AU2018207946B2 publication Critical patent/AU2018207946B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2018207946A 2017-01-12 2018-01-12 Probiotic compositions and uses thereof Active AU2018207946B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1700542.2 2017-01-12
GBGB1700542.2A GB201700542D0 (en) 2017-01-12 2017-01-12 Probiotic compositions and uses thereof
GBGB1709731.2A GB201709731D0 (en) 2017-06-19 2017-06-19 Probiotic compositions and uses thereof
GB1709731.2 2017-06-19
PCT/EP2018/050789 WO2018130667A1 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2018207946A1 AU2018207946A1 (en) 2019-07-25
AU2018207946B2 true AU2018207946B2 (en) 2024-07-18

Family

ID=61386800

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018207946A Active AU2018207946B2 (en) 2017-01-12 2018-01-12 Probiotic compositions and uses thereof

Country Status (14)

Country Link
US (1) US11166993B2 (enExample)
EP (1) EP3568144B1 (enExample)
JP (1) JP7089523B2 (enExample)
KR (1) KR102500496B1 (enExample)
CN (1) CN110177561B (enExample)
AU (1) AU2018207946B2 (enExample)
BR (1) BR112019014418A2 (enExample)
CA (1) CA3049624A1 (enExample)
CL (1) CL2019001938A1 (enExample)
MX (1) MX2019008292A (enExample)
MY (1) MY195253A (enExample)
PH (1) PH12019501629A1 (enExample)
RU (1) RU2763311C2 (enExample)
WO (1) WO2018130667A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013439A (es) * 2018-06-18 2021-05-12 Probi Ab Composiciones probioticas y usos de las mismas.
IT201900014550A1 (it) * 2019-08-09 2021-02-09 Abiogen Pharma Spa Uso di colecalciferolo come agente attivo nel trattamento della celiachia
CN116869141A (zh) * 2022-05-05 2023-10-13 内蒙古一康健康发展有限责任公司 一种具有保健功能的益生菌复合物及其制备方法
KR102845919B1 (ko) * 2023-02-28 2025-08-14 주식회사 피엘비앤비 장내 유해세균의 성장 억제 성능이 우수한 한국인 모유 유래 락티카제이바실러스 파라카제이 pl1536 및 이를 유효성분으로 포함하는 기능성식품 조성물
CN119279210A (zh) * 2024-12-16 2025-01-10 山东健源生物科技有限公司 一种复合益生菌发酵含药食同源物质的多谷物后生元制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004076615A2 (en) * 2003-02-27 2004-09-10 Bioneer A/S Immunomodulating probiotic compounds
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
ZA200802934B (en) * 2005-10-06 2009-09-30 Probi Ab Use of lactobacillus for treatment of virus infections
EP1951273B1 (en) 2005-10-06 2014-02-12 Probi Ab Use of lactobacillus for treatment of autoimmune diseases
PL1996696T3 (pl) 2006-03-17 2017-08-31 Probi Aktiebolag Termostabilne szczepy Lactobacillus
WO2007108763A1 (en) * 2006-03-17 2007-09-27 Probac Ab Use of lactobacillus strains for promoting immunotolerance in autoimmune disease
PT2367561E (pt) 2008-11-30 2015-10-23 Immusant Inc Composições e métodos para o tratamento da doença celíaca
EP2581461B1 (en) * 2011-10-14 2014-09-24 GenMont Biotech Incorporation Composition and use of lactobacillus paracasei strain GMNL-133 in treating atopic dermatitis or other allergic diseases
RU2654705C2 (ru) * 2012-06-18 2018-05-22 Г.Дж. Хайнц Компани Брэндс ЛЛК Глютенозависимые расстройства
AU2014250113B2 (en) * 2013-04-03 2017-03-30 Probi Ab Probiotic strains for use in treatment or prevention of osteoporosis
WO2016083450A2 (en) * 2014-11-25 2016-06-02 Stichting Top Institute Food And Nutrition New probiotic and new biomarker

Also Published As

Publication number Publication date
EP3568144C0 (en) 2024-05-08
EP3568144A1 (en) 2019-11-20
MY195253A (en) 2023-01-11
US11166993B2 (en) 2021-11-09
CN110177561B (zh) 2023-09-12
CL2019001938A1 (es) 2019-09-27
CA3049624A1 (en) 2018-07-19
AU2018207946A1 (en) 2019-07-25
PH12019501629A1 (en) 2020-06-01
KR102500496B1 (ko) 2023-02-16
RU2763311C2 (ru) 2021-12-28
EP3568144B1 (en) 2024-05-08
US20190358275A1 (en) 2019-11-28
RU2019121145A (ru) 2021-02-12
MX2019008292A (es) 2019-09-16
CN110177561A (zh) 2019-08-27
RU2019121145A3 (enExample) 2021-04-26
BR112019014418A2 (pt) 2020-04-14
JP7089523B2 (ja) 2022-06-22
WO2018130667A1 (en) 2018-07-19
JP2020513780A (ja) 2020-05-21
KR20190104568A (ko) 2019-09-10

Similar Documents

Publication Publication Date Title
AU2018207946B2 (en) Probiotic compositions and uses thereof
Miyazawa et al. Heat-killed Lactobacillus gasseri can enhance immunity in the elderly in a double-blind, placebo-controlled clinical study
Cook et al. Circulating gluten-specific FOXP3+ CD39+ regulatory T cells have impaired suppressive function in patients with celiac disease
Hornsby et al. Vitamin D supplementation during pregnancy: effect on the neonatal immune system in a randomized controlled trial
AU2006297895B2 (en) Use of lactobacillus for treatment of virus infections
Sellitto et al. Proof of concept of microbiome-metabolome analysis and delayed gluten exposure on celiac disease autoimmunity in genetically at-risk infants
EP4014982B1 (en) Composition for inducing proliferation or accumulation of regulatory t cells
Hardy et al. Consistency in polyclonal T-cell responses to gluten between children and adults with celiac disease
Kaukinen et al. Coeliac disease-a diagnostic and therapeutic challenge.
EP3310367A1 (en) Induction of lamina propria regulatory t cells
Kim et al. Identification of atopic dermatitis phenotypes with good responses to probiotics (Lactobacillus plantarum CJLP133) in children
Sredkova et al. Prebiotics can change immunomodulatory properties of probiotics
US11590181B2 (en) Serpin production
Dons’koi et al. HCMV seropositivity is associated with specific proinflammatory immune phenotype in women with implantation failure
EP3019864A1 (en) Diagnosis, prognosis and treatment of inflammatory bowel diseases
JP2008099632A (ja) 免疫賦活作用・抗アレルギー作用を有する乳酸菌
Enomoto et al. Oral administration of Lactobacillus plantarum NRIC0380 suppresses IgE production and induces CD4+ CD25+ Foxp3+ cells in vivo
Huang et al. Propionic fermentation by the probiotic Propionibacterium freudenreichii to functionalize whey
CN1492764A (zh) 整肠剂
Talayev et al. Cytokine profile of CCR6+ T-helpers isolated from the blood of patients with peptic ulcer associated with Helicobacter pylori infection
Cao et al. Effect of thymectomy on cellular immune function
Noorifard et al. Effects of probiotic supplementation on immune response in soldiers: a randomized, double-blinded, placebo-controlled trial
Zhao Immune responses alter in heterogeneous nuclear ribonucleoprotein I knockout mice with medium protein diet or probiotic intervention
Berryman Genetic Risk for Autoimmunity Is Associated With Potential for Dysbiosis and Inflammation Early in Life
Hungerford Coeliac disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)